MODERNA investigates its personalized mRNA cancer vaccine with pembrolizumab to prevent recurrence in resected, high-risk melanoma. The Phase 3 randomized trial, designated INTerpath-001 or V940-001, evaluates the clinical efficacy and safety of intismeran autogene in combination with immune checkpoint inhibition. Conducted in adult patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV cutaneous melanoma, this global study addresses a crucial clinical challenge in adjuvant oncology. Despite definitive surgical resection, patients presenting with deep primary lesions or regional nodal involvement face high recurrence rates and distant metastatic progression.
The investigational therapeutic regimen combines intismeran autogene, a personalized neoantigen therapy, with the programmed cell death protein 1 inhibitor pembrolizumab. Each synthetic mRNA construct is designed to encode up to thirty-four patient-specific neoantigens identified through comprehensive next-generation sequencing of surgically resected tumor tissue. Upon intramuscular administration, the lipid nanoparticle formulated mRNA stimulates endogenous antigen-presenting cells, priming a robust, polyclonal cytotoxic T-cell response against residual micrometastatic cells. Concurrently, pembrolizumab blocks PD-1 inhibitory checkpoint signaling, reversing tumor-mediated immune suppression.
Eligible trial participants are randomized to receive either the Moderna mRNA cancer vaccine in combination with standard pembrolizumab or pembrolizumab monotherapy with matching placebo. The primary efficacy endpoint is recurrence-free survival assessed by investigator review, while secondary outcome measures include distant metastasis-free survival, overall survival, and comprehensive adverse event profiles.
For dermatologists, surgical oncologists, and multidisciplinary cancer care teams, the trial represents a promising advance in personalized oncology care. Prior clinical investigations demonstrated that combining individualized neoantigen vaccination with standard checkpoint blockade significantly reduced the risk of recurrence compared to monotherapy alone. Routine monitoring protocols in ongoing investigations evaluate immune-related adverse events, localized injection site reactions, and systemic tolerability to ensure therapy does not impair functional recovery. As clinical teams navigate expanding immunotherapeutic options, integrating the Moderna mRNA cancer vaccine into post-resection protocols may provide a potent strategy to achieve durable remission in high-risk cutaneous melanoma.
Reference
ClinicalTrials.gov. A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001). ClinicalTrials.gov. 2026;NCT05933577.
Featured Image: Evgeniy Kalinovskiy on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
